Abstract
Background: Pancreatic cancer continues to be one of the most aggressive malignant tumors. Work in recent years in cancer molecular biology has revealed that metabolic reprogramming is an additional hallmark of cancer that is involved in the pathogenesis of cancers, and is intricately linked to gene mutations. Main text: However, though oncogenes such as KRAS and c-Myc play important roles in the process, and have been extensively studied, no substantial improvements in the prognosis of pancreatic cancer have seen. Therefore, some scientists have tried to explain the mechanisms of abnormal cancer metabolism from the perspective of tumor suppressor genes. In this paper, we reviewed researches about how metabolic reprogramming was regulated by tumor suppressor genes in pancreatic cancer and their clinical implications. Conclusion: Abnormal metabolism and genetic mutations are mutually causal and complementary in tumor initiation and development. A clear understanding of how metabolic reprogramming is regulated by the mutated genes would provide important insights into the pathogenesis and ultimately treatment of pancreatic cancer.
Author supplied keywords
Cite
CITATION STYLE
Liu, M., Liu, W., Qin, Y., Xu, X., Yu, X., Zhuo, Q., & Ji, S. (2020, September 3). Regulation of metabolic reprogramming by tumor suppressor genes in pancreatic cancer. Experimental Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s40164-020-00179-x
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.